glp 1 and bodybuilding Semaglutide Building Muscle While on a

The medication is still preventing the full regain that would occur without it

In people with obesity, 36 weeks of orforglipron (doses ranging from 12 to 45 mg in a phase 2 trial) resulted in a dose-dependent WL up to 14.7% compared to 2.3% with placebo, with concomitant improvement in cardiometabolic risk factors (Table 2) [25]

Active Ingredient : Semaglutide, a GLP-1 receptor agonist Mechanism of Action : According to FDA prescribing information, semaglutide works by: Increasing glucose-dependent insulin secretion Decreasing glucagon secretion Slowing gastric emptying Acting on centers in the brain that regulate appetite Clinical Trial Evidence - STEP Program : According to published data from the STEP 1 trial (New England Journal of Medicine, 2021): Study Design : 68-week randomized, double-blind, placebo-controlled trial 1,961 adults without diabetes Inclusion: BMI 30 or 27 with weight-related conditions Intervention: Once-weekly subcutaneous semaglutide 2.4 mg Lifestyle: 500-calorie deficit diet plus 150 minutes/week physical activity Primary Results : Semaglutide group: Average 14.9% body weight loss (approximately 33 lbs for 220 lb individual) Placebo group: Average 2.4% body weight loss (approximately 5 lbs for 220 lb individual) Difference: 12.4 percentage points (p0.001 for superiority) Secondary Results : 50.5% of semaglutide participants lost 15% body weight (vs 4.9% placebo) 86.4% of semaglutide participants lost 5% body weight (vs 31.5% placebo) 69.1% of semaglutide participants lost 10% body weight (vs 12.0% placebo) Progressive Weight Loss Timeline (STEP 1 data): Week 8: Approximately 4% body weight reduction Week 20: Approximately 10.6% body weight reduction Week 40: Approximately 13% body weight reduction Week 68: Approximately 15% body weight reduction (endpoint) Clinical Trial Disclaimer: Results represent averages from controlled research settings

It has a multi-year operational track record

FDA Regulatory Notice: As of February 2026, the FDA has resolved the semaglutide drug shortage and has stated its intent to prioritize enforcement against certain mass-marketed non-FDA-approved GLP-1 products

Such medications risk suppressing appetite excessively, which can potentially lead to conditions mimicking Avoidant/Restrictive Food Intake Disorder (ARFID)